Drugs that contain Pegcetacoplan
1. List of Empaveli drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9169307 | APELLIS PHARMS | Potent compstatin analogs |
Nov, 2027
(4 years from now) | |
| US7888323 | APELLIS PHARMS | Potent compstatin analogs |
Dec, 2027
(4 years from now) | |
| US7989589 | APELLIS PHARMS | Compstatin analogs with improved activity |
Dec, 2027
(4 years from now) | |
| US10125171 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Aug, 2033
(10 years from now) | |
| US11292815 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(10 years from now) | |
| US10875893 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(10 years from now) | |
| US10035822 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11040107 | APELLIS PHARMS | Dosing regimens and related compositions and methods |
Apr, 2038
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 14, 2026 |
| Orphan Drug Exclusivity (ODE) | May 14, 2028 |
NCE-1 date: May, 2025
Market Authorisation Date: 14 May, 2021
Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan; Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan every three days; Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan twice weekly; Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of complement inhibitor pegcetacoplan; Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of pegcetacoplan; Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of pegcetacoplan so as to reduce the sensitivity of cells to complement-dependent damage
Dosage: SOLUTION;SUBCUTANEOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic